Yiyun Huang, PhD
Professor of Radiology and Biomedical Imaging; Co-Director of Yale PET Center & Director of Chemistry
Research & Publications
Biography
News
Research Summary
The main focus of Dr. Henry Huang's research is the development of new and improved Positron Emission Tomography (PET) radioligands. PET ligand development is a process that involves the interplays of chemistry, biology, pharmacology and pharmacokinetics, and it requires a good understanding of all these scientific disciplines. Over the years Dr. Huang has been involved in the development of new or improved PET radioligands for the dopamine, serotonin, glutamate and acetylcholine receptors and transporters in the brain. Development of PET radioligands includes the following stages: 1. design and synthesis of candidate ligands; 2. in vitro pharmacological experiments to determine binding affinities and selectivity. 3. design and execution of biological and pharmacological experiments in live animals including rodents and non-human primates to evaluate the ligands’ in vivo pharmacology and pharmacokinetics such as distribution, binding selectivity and specificity, metabolism, clearance, and blood and brain kinetics; 4. determination of dosimetry and toxicology; 5. clinical trials to determine the ligands’ suitability for applications in humans to image targeted receptors, proteins, or enzymes. PET imaging technique can be used to determine the concentrations of CNS receptors and transporters in discrete brain regions under normal conditions. It can also be used to probe the changes in the densities of certain receptors and transporters in diseases. Coupled with pharmacological manipulation or stimulation, PET imaging is capable of probing the abnormality in the neurotransmission system functions under diseased conditions.
Extensive Research Description
The main focus of Dr. Henry Huang's research is the development of new and improved Positron Emission Tomography (PET) radioligands. PET ligand development is a process that involves the interplays of chemistry, biology, pharmacology and pharmacokinetics, and it requires a good understanding of all these scientific disciplines. Over the years Dr. Huang has been involved in the development of new or improved PET radioligands for the dopamine, serotonin, glutamate and acetylcholine receptors and transporters in the brain. Development of PET radioligands includes the following stages: 1. design and synthesis of candidate ligands; 2. in vitro pharmacological experiments to determine binding affinities and selectivity. 3. design and execution of biological and pharmacological experiments in live animals including rodents and non-human primates to evaluate the ligands’ in vivo pharmacology and pharmacokinetics such as distribution, binding selectivity and specificity, metabolism, clearance, and blood and brain kinetics; 4. determination of dosimetry and toxicology; 5. clinical trials to determine the ligands’ suitability for applications in humans to image targeted receptors, proteins, or enzymes.
PET imaging technique can be used to determine the concentrations of CNS receptors and transporters in discrete brain regions under normal conditions. It can also be used to probe the changes in the densities of certain receptors and transporters in diseases. Coupled with pharmacological manipulation or stimulation, PET imaging is capable of probing the abnormality in the neurotransmission system functions under diseased conditions. Further applications include determination of the receptor occupancy by marketed or experimental drugs and monitoring the outcome of drug treatment for diseases. In all these applications the key is the availability of an appropriate PET radioligand for a specific receptor, transporter, or enzyme. Therefore, development of PET radioligands is a critical component of PET imaging and will continue to be the major part of Dr. Huang's research. His current interest is the development of ligands for targets in the CNS encompassing many of the neurotransmission systems.
Coauthors
Selected Publications
- Evaluation of a First PET Tracer Suitable for Imaging the Sigma‑2 Receptor in the Brain of Nonhuman PrimatesAlluri S, Zheng M, Holden D, Zhang Y, Zhang L, Felchner Z, Li S, Ropchan J, Carson R, Jia H, Huang Y. Evaluation of a First PET Tracer Suitable for Imaging the Sigma‑2 Receptor in the Brain of Nonhuman Primates. Molecular Pharmaceutics 2023, 21: 194-200. PMID: 38013422, DOI: 10.1021/acs.molpharmaceut.3c00750.
- The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-JToyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
- Development of a Highly Specific 18F‑Labeled Radioligand for Imaging of the Sigma‑2 Receptor in Brain TumorsWang T, Wang J, Chen L, Zhang X, Mou T, An X, Zhang J, Zhang X, Deuther-Conrad W, Huang Y, Jia H. Development of a Highly Specific 18F‑Labeled Radioligand for Imaging of the Sigma‑2 Receptor in Brain Tumors. Journal Of Medicinal Chemistry 2023, 66: 12840-12857. PMID: 37704582, DOI: 10.1021/acs.jmedchem.3c00735.
- Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PETSilva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Varma P, Toyonaga T, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET. American Journal Of Geriatric Psychiatry 2023, 32: 17-28. PMID: 37673749, PMCID: PMC10840732, DOI: 10.1016/j.jagp.2023.08.002.
- Imaging the brain’s immune response to alcohol with [11C]PBR28 TSPO Positron Emission TomographyRaval N, Angarita G, Matuskey D, Miller R, Drake L, Kapinos M, Nabulsi N, Huang Y, Carson R, O’Malley S, Cosgrove K, Hillmer A. Imaging the brain’s immune response to alcohol with [11C]PBR28 TSPO Positron Emission Tomography. Molecular Psychiatry 2023, 28: 3384-3390. PMID: 37532797, PMCID: PMC10743097, DOI: 10.1038/s41380-023-02198-6.
- Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.
- 18F-Labeled o‑aminopyridyl alkynyl radioligands targeting colony-stimulating factor 1 receptor for neuroinflammation imagingAn X, Wang J, Tong L, Zhang X, Fu H, Zhang J, Xie H, Huang Y, Jia H. 18F-Labeled o‑aminopyridyl alkynyl radioligands targeting colony-stimulating factor 1 receptor for neuroinflammation imaging. Bioorganic & Medicinal Chemistry 2023, 83: 117233. PMID: 36933438, DOI: 10.1016/j.bmc.2023.117233.
- Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primatesChen B, Ojha D, Toyonaga T, Tong J, Pracitto R, Thomas M, Liu M, Kapinos M, Zhang L, Zheng M, Holden D, Fowles K, Ropchan J, Nabulsi N, De Feyter H, Carson R, Huang Y, Cai Z. Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 50: 2081-2099. PMID: 36849748, DOI: 10.1007/s00259-023-06162-y.
- Decreased synaptic vesicle glycoprotein 2A binding in a rodent model of familial Alzheimer's disease detected by [18F]SDM-16Zheng C, Toyonaga T, Chen B, Nicholson L, Mennie W, Liu M, Spurrier J, Deluca K, Strittmatter S, Carson R, Huang Y, Cai Z. Decreased synaptic vesicle glycoprotein 2A binding in a rodent model of familial Alzheimer's disease detected by [18F]SDM-16. Frontiers In Neurology 2023, 14: 1045644. PMID: 36846134, PMCID: PMC9945093, DOI: 10.3389/fneur.2023.1045644.
- Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humansSawant‐Basak A, Chen L, Lockwood P, Boyden T, Doran A, Mancuso J, Zasadny K, McCarthy T, Morris E, Carson R, Esterlis I, Huang Y, Nabulsi N, Planeta B, Fullerton T. Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humans. Biopharmaceutics & Drug Disposition 2023, 44: 48-59. PMID: 36825693, DOI: 10.1002/bdd.2351.
- In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer’s diseaseZhang J, Wang J, Xu X, You Z, Huang Q, Huang Y, Guo Q, Guan Y, Zhao J, Liu J, Xu W, Deng Y, Xie F, Li B. In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer’s disease. Cerebrovascular And Brain Metabolism Reviews 2023, 43: 977-988. PMID: 36718002, PMCID: PMC10196742, DOI: 10.1177/0271678x231153730.
- In Vivo Imaging and Kinetic Modeling of Novel Glycogen Synthase Kinase-3 Radiotracers [11C]OCM-44 and [18F]OCM-50 in Non-Human PrimatesSmart K, Zheng M, Holden D, Felchner Z, Zhang L, Han Y, Ropchan J, Carson R, Vasdev N, Huang Y. In Vivo Imaging and Kinetic Modeling of Novel Glycogen Synthase Kinase-3 Radiotracers [11C]OCM-44 and [18F]OCM-50 in Non-Human Primates. Pharmaceuticals 2023, 16: 194. PMID: 37259346, PMCID: PMC9959234, DOI: 10.3390/ph16020194.
- Cholinergic system adaptations are associated with cognitive function in people recently abstinent from smoking: a (-)-[18F]flubatine PET studyCalakos K, Hillmer A, Anderson J, LeVasseur B, Baldassarri S, Angarita G, Matuskey D, Kapinos M, Zheng M, Huang Y, Cosgrove K. Cholinergic system adaptations are associated with cognitive function in people recently abstinent from smoking: a (-)-[18F]flubatine PET study. Neuropsychopharmacology 2023, 48: 683-689. PMID: 36681758, PMCID: PMC9938267, DOI: 10.1038/s41386-023-01535-1.
- Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetineRosell D, Slifstein M, Thompson J, Xu X, Perez-Rodriguez M, McClure M, Hazlett E, New A, Nabulsi N, Huang Y, Carson R, Siever L, Abi-Dargham A, Koenigsberg H. Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine. Psychopharmacology 2023, 240: 361-371. PMID: 36640190, DOI: 10.1007/s00213-022-06306-2.
- First-in-Human PET Imaging of [18F]SDM-4MP3: A Cautionary TaleDesmond K, Lindberg A, Garcia A, Tong J, Harkness M, Dobrota E, Smart K, Uribe C, Meyer J, Houle S, Strafella A, Li S, Huang Y, Vasdev N. First-in-Human PET Imaging of [18F]SDM-4MP3: A Cautionary Tale. Molecular Imaging 2023, 2023: 8826977. PMID: 37719326, PMCID: PMC10504053, DOI: 10.1155/2023/8826977.
- Visualization of synaptic vesicle protein 2A in a rodent model of familial Alzheimer’s disease with a metabolically stable PET probeZheng C, Chen B, Toyonaga T, Liu M, Nicholson L, Deluca K, Strittmatter S, Carson R, Huang Y, Cai Z. Visualization of synaptic vesicle protein 2A in a rodent model of familial Alzheimer’s disease with a metabolically stable PET probe. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063890.
- Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PETSalardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065064.
- Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PETSalardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065162.
- Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDGO'Dell R, Mecca A, Waszak J, Sharp E, Chen M, Naganawa M, Toyonaga T, Lu Y, Chupak A, Cooper E, Lam J, Miller A, Waldner E, Weibley H, Zhao Y, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDG. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.062595.
- Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adultsMatuskey D, Gallezot J, Nabulsi N, Henry S, Torres K, Dias M, Angarita G, Huang Y, Shoaf S, Carson R, Mehrotra S. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults. Journal Of Psychopharmacology 2022, 37: 164-171. PMID: 36515395, PMCID: PMC9912308, DOI: 10.1177/02698811221140008.
- Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2ANaganawa M, Gallezot J, Finnema S, Maguire R, Mercier J, Nabulsi N, Kervyn S, Henry S, Nicolas J, Huang Y, Chen M, Hannestad J, Klitgaard H, Stockis A, Carson R. Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A. EJNMMI Research 2022, 12: 71. PMID: 36346513, PMCID: PMC9643320, DOI: 10.1186/s13550-022-00944-5.
- Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand: (S)-(+)- and (R)-(-)-[18F]FBFPWang T, Zhang Y, Zhang X, Chen L, Zheng M, Zhang J, Brust P, Deuther-Conrad W, Huang Y, Jia H. Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand: (S)-(+)- and (R)-(-)-[18F]FBFP. Chinese Chemical Letters 2022, 33: 3543-3548. DOI: 10.1016/j.cclet.2022.03.099.
- Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target EngagementLee H, Blumberger D, Lenze E, Anderson S, Barch D, Black K, Cristancho P, Daskalakis Z, Eisenstein S, Huang Y, Li S, Lissemore J, McConathy J, Mulsant B, Rajji T, Reynolds C, Su Y, Tu Z, Voineskos D, Karp J. Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement. Biological Psychiatry Global Open Science 2021, 2: 127-135. PMID: 36325158, PMCID: PMC9616305, DOI: 10.1016/j.bpsgos.2021.09.003.
- Chapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug developmentHuang Y, Jia H, Bao W. Chapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. 2021, 367-412. DOI: 10.1016/b978-0-12-816475-4.00013-6.
- PET Imaging of Synaptic Vesicle Protein 2AFinnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.
- The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Cravingde Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.
- Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNOBini J, Naganawa M, Nabulsi N, Huang Y, Ropchan J, Lim K, Najafzadeh S, Herold KC, Cline GW, Carson RE. Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO. Journal Of Nuclear Medicine 2018, 59: 1249-1254. PMID: 29371405, PMCID: PMC6071501, DOI: 10.2967/jnumed.117.197285.
- PET/fMRI for precise localization of abnormal brain activity: a mini reviewZang Y, Feng F, Huo L, Li B, Lan X, Lu J, Tian J, Zhao Z, Huang Y. PET/fMRI for precise localization of abnormal brain activity: a mini review. Chinese Journal Of Nuclear Medicine And Molecular Imaging 2017, 37: 802-808. DOI: 10.3760/cma.j.issn.2095-2848.2017.12.014.
- Systemic inflammation enhances stimulant-induced striatal dopamine elevationPetrulli J, Kalish B, Nabulsi N, Huang Y, Hannestad J, Morris E. Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Translational Psychiatry 2017, 7: e1076-e1076. PMID: 28350401, PMCID: PMC5404612, DOI: 10.1038/tp.2017.18.
- Brivaracetam (BRV) Achieves Brain SV2A Occupancy Faster than Levetiracetam (LEV) (S22.003)Mercier J, Holden D, Deo A, Fowles K, Kervyn S, Nabulsi N, Nicolas J, Klitgaard H, Huang Y, D'Souza J, Carson R, Hannestad J. Brivaracetam (BRV) Achieves Brain SV2A Occupancy Faster than Levetiracetam (LEV) (S22.003). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.s22.003.
- Segmentation of Rat Spinal Cord in PET Using Spatiotemporal InformationFung E, Weinzimmer D, Strittmatter S, Huang Y, Carson R. Segmentation of Rat Spinal Cord in PET Using Spatiotemporal Information. 2010, 3605-3609. DOI: 10.1109/nssmic.2010.5874483.
- Erratum: Cocaine Dependence and D2 Receptor Availability in Functional Subdivisions of the Striatum: Relationship with Cocaine-Seeking BehaviorMartinez D, Broft A, Foltin R, Slifstein M, Hwang D, Huang Y, Perez A, Frankle W, Cooper T, Kleber H, Fischman M, Laruelle M. Erratum: Cocaine Dependence and D2 Receptor Availability in Functional Subdivisions of the Striatum: Relationship with Cocaine-Seeking Behavior. Neuropsychopharmacology 2004, 29: 1763-1763. DOI: 10.1038/sj.npp.1300499.
- Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the StriatumMartinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M. Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum. Cerebrovascular And Brain Metabolism Reviews 2003, 23: 285-300. PMID: 12621304, DOI: 10.1097/01.wcb.0000048520.34839.1a.
- Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFMHuang Y, Hwang D, Narendran R, Sudo Y, Chatterjee R, Bae S, Mawlawi O, Kegeles L, Wilson A, Kung H, Laruelle M. Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. Cerebrovascular And Brain Metabolism Reviews 2002, 22: 1377-1398. DOI: 10.1097/00004647-200211000-00011.
- Imaging Human Mesolimbic Dopamine Transmission With Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral StriatumMawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang D, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M. Imaging Human Mesolimbic Dopamine Transmission With Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum. Cerebrovascular And Brain Metabolism Reviews 2001, 21: 1034-1057. PMID: 11524609, DOI: 10.1097/00004647-200109000-00002.
- Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights.Laruelle M, Huang Y. Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Quarterly Journal Of Nuclear Medicine And Molecular Imaging 2001, 45: 124-38. PMID: 11476162.
- Synthesis of potent and selective dopamine D4 antagonists as candidate radioligandsHuang Y, Kegeles L, Bae S, Hwang D, Roth B, Savage J, Laruelle M. Synthesis of potent and selective dopamine D4 antagonists as candidate radioligands. Bioorganic & Medicinal Chemistry Letters 2001, 11: 1375-1377. PMID: 11378358, DOI: 10.1016/s0960-894x(01)00241-4.
- Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboonsPrice J, Lopresti B, Mason N, Holt D, Huang Y, Mathis C. Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons. Synapse 2001, 41: 1-10. PMID: 11354008, DOI: 10.1002/syn.1054.
- Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humansPrice J, Lopresti B, Meltzer C, Smith G, Mason N, Huang Y, Holt D, Gunn R, Mathis C. Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans. Synapse 2001, 41: 11-21. PMID: 11354009, DOI: 10.1002/syn.1055.
- Preparation and evaluation of [F‐18]‐labeled 5‐HT1A Agonist: 1‐[2‐(4‐[F‐18]Fluorobenzamido)‐1‐Ethyl]‐4‐(1,2,3,4‐Tetrahydronaphth‐1‐YL)‐Piperidine (FBP)Hwang D, Ngo K, Savenkova L, Huang Y, Guo N, Zhu Z, Laruelle M. Preparation and evaluation of [F‐18]‐labeled 5‐HT1A Agonist: 1‐[2‐(4‐[F‐18]Fluorobenzamido)‐1‐Ethyl]‐4‐(1,2,3,4‐Tetrahydronaphth‐1‐YL)‐Piperidine (FBP). Journal Of Labelled Compounds And Radiopharmaceuticals 2001, 44: s179-s181. DOI: 10.1002/jlcr.2580440162.
- Preparation and evaluation of [11C]‐labeled 5HT1A agonist: (R)‐10‐Methyl‐11‐hydroxyaporphineHwang D, Huang Y, Ngo K, Savenkova L, Guo N, Zhu Z, Laruelle M. Preparation and evaluation of [11C]‐labeled 5HT1A agonist: (R)‐10‐Methyl‐11‐hydroxyaporphine. Journal Of Labelled Compounds And Radiopharmaceuticals 2001, 44: s176-s178. DOI: 10.1002/jlcr.2580440161.
- Fluorinated analogues of ADAM as new PET radioligands for the serotonin transporter: Synthesis and pharmacological evaluationHuang Y, Bae S, Zhu Z, Guo N, Hwang D, Laruelle M. Fluorinated analogues of ADAM as new PET radioligands for the serotonin transporter: Synthesis and pharmacological evaluation. Journal Of Labelled Compounds And Radiopharmaceuticals 2001, 44: s18-s20. DOI: 10.1002/jlcr.2580440107.
- Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in HumansMartinez D, Hwang D, Mawlawi O, Slifstein M, Kent J, Simpson N, Parsey R, Hashimoto T, Huang Y, Shinn A, Van Heertum R, Abi-Dargham A, Caltabiano S, Malizia A, Cowley H, Mann J, Laruelle M. Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans. Neuropsychopharmacology 2001, 24: 209-229. PMID: 11166513, DOI: 10.1016/s0893-133x(00)00187-1.
- Positron emission tomography study of pindolol occupancy of 5-HT1A receptors in humans: preliminary analysesMartinez D, Mawlawi O, Hwang D, Kent J, Simpson N, Parsey R, Hashimoto T, Slifstein M, Huang Y, Van Heertum R, Abi-Dargham A, Caltabiano S, Malizia A, Cowley H, Mann J, Laruelle M. Positron emission tomography study of pindolol occupancy of 5-HT1A receptors in humans: preliminary analyses. Nuclear Medicine And Biology 2000, 27: 523-527. PMID: 10962261, DOI: 10.1016/s0969-8051(00)00122-0.
- Pet imaging of serotonin 1A receptor binding in depressionDrevets W, Frank E, Price J, Kupfer D, Holt D, Greer P, Huang Y, Gautier C, Mathis C. Pet imaging of serotonin 1A receptor binding in depression. Biological Psychiatry 1999, 46: 1375-1387. PMID: 10578452, DOI: 10.1016/s0006-3223(99)00189-4.
- An efficient synthesis of the precursors of [11C]MDL 100907 labeled in two specific positionsHuang Y, Mahmood K, Mathis C. An efficient synthesis of the precursors of [11C]MDL 100907 labeled in two specific positions. Journal Of Labelled Compounds And Radiopharmaceuticals 1999, 42: 949-957. DOI: 10.1002/(sici)1099-1344(199910)42:10<949::aid-jlcr253>3.0.co;2-s.
- Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brainSmith G, Price J, Lopresti B, Huang Y, Simpson N, Holt D, Mason N, Meltzer C, Sweet R, Nichols T, Sashin D, Mathis C. Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain. Synapse 1998, 30: 380-392. PMID: 9826230, DOI: 10.1002/(sici)1098-2396(199812)30:4<380::aid-syn5>3.0.co;2-u.
- Radioligands for PET Studies of Serotonin 5-HT2A ReceptorsMathis C, Price J, Lopresti B, Smith G, Meltzer C, Holt D, Mason N, Huang Y. Radioligands for PET Studies of Serotonin 5-HT2A Receptors. NeuroImage 1998, 7: a40. DOI: 10.1016/s1053-8119(18)31909-8.
- Chapter 64 [18F]Altanserin PET Studies of Serotonin-2A Binding Examination of Nonspecific ComponentPrice J, Lopresti B, Mason N, Huang Y, Holt D, Smith G, Mathis C. Chapter 64 [18F]Altanserin PET Studies of Serotonin-2A Binding Examination of Nonspecific Component. 1998, 427-434. DOI: 10.1016/b978-012161340-2/50066-4.
- Chapter 44 Characterization of the Radiolabeled Metabolites of [18F]Altanserin Implications for Kinetic ModelingLopresti B, Holt D, Mason N, Huang Y, Ruszkiewicz J, Perevuznik J, Price J, Smith G, Davis J, Mathis C. Chapter 44 Characterization of the Radiolabeled Metabolites of [18F]Altanserin Implications for Kinetic Modeling. 1998, 293-298. DOI: 10.1016/b978-012161340-2/50046-9.
- Stereoconservative synthesis of the enantiomerically pure precursors of [11C](+)‐McN 5652 and [11C](−)‐McN 5652Huang Y, Mahmood K, Simpson N, Mason N, Mathis C. Stereoconservative synthesis of the enantiomerically pure precursors of [11C](+)‐McN 5652 and [11C](−)‐McN 5652. Journal Of Labelled Compounds And Radiopharmaceuticals 1998, 41: 9-17. DOI: 10.1002/(sici)1099-1344(199801)41:1<9::aid-jlcr47>3.0.co;2-8.
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Nervous System | Study of Safety and of the Mechanism of BLZ945 in ALS Patients |
Mental Health & Behavioral Research | HPA axis function in the brains of PTSD, Trauma Exposed, or Otherwise Healthy research participants utilizing PET and MRI imaging |
Diseases of the Nervous System | Imaging the Dopamine Transporter in Parkinson's Disease |
Diseases of the Nervous System | Imaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO |
Diseases of the Nervous System; Mental Health & Behavioral Research | SV2A PET Imaging in Healthy Subjects and Epilepsy Patients |
Addictive Behaviors; Diseases of the Nervous System; Genetics - Adult; Mental Health & Behavioral Research | Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning |
Obesity & Weight Control | Imaging cortisol metabolism in liver, adipose tissue and brain with a novel PET radioligand |